MDCO Beats, Ties With AstraZeneca
Posted on April 26, 2012 at 14:43 PM EDT
The Medicines Company (NASDAQ:MDCO) reported first quarter earnings of 21 cents per share, including the impact of stock-based compensation expense. First quarter earnings, while well above the Zacks Consensus Estimate of 11 cents, declined 65% from the year-ago earnings. Although first quarter 2012 revenues were higher, higher operating expenses led to the year-over-year decline in [...]

The Medicines Company (NASDAQ:MDCO) reported first quarter earnings of 21 cents per share, including the impact of stock-based compensation expense. First quarter earnings, while well above the Zacks Consensus Estimate of 11 cents, declined 65% from the year-ago earnings.
Although first quarter 2012 revenues were higher, higher operating expenses led to the year-over-year decline in earnings. Revenues, up 12.9% at $126.6 million, were above the Zacks Consensus Estimate of $124 million.
The Quarter … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards


Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here